🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07558629
Active, not recruiting Observational

SH-SDU Shandong Endometriosis Reproductive Cohort

NCT07558629 · tracked via the Priya Life Science China tracker
Sponsor
The Second Hospital of Shandong University
Phase
Observational
Started
2025-10-14
Last updated
2026-04-30

Condition(s) studied

EndometriosisOmicsAssisted Reproductive Technology

Study summary

Endometriosis (EMs) is a chronic, estrogen-dependent, multi-systemic disease that affects approximately 190 million women worldwide. EMs can increase the risk of miscarriage, and even mild EMs can negatively affect fertilization and implantation rates. Some meta-analyses have reported that EMs increases the risk of adverse obstetric outcomes, such as preterm birth and cesarean section, and also increases the risk of neonatal hospitalization. In addition to affecting pregnancy outcomes in women of reproductive age, EMs has significant social and psychological impacts on women of all ages in multiple areas of life, and can further affect the entire family, leading to substantial economic burdens and reduced quality of life. Finally, due to the increased incidence of the disease in the offspring of EMs patients, long-term follow-up is also a key aspect of disease management. To improve clinical practice and enhance fertility in EMs patients, more evidence is needed to meet the key priorities of future research. Integrated analysis of comprehensive case resources and clinical data can provide a reliable research foundation for future personalized diagnosis and treatment. High-quality and traceable large biobanks are a crucial resource for exploring pathogenic mechanisms. Prospective cohort studies conducted on this basis are expected to investigate the impact of the disease on patient clinical outcomes and further explore the disease's pathogenesis, aiming to identify physiological pathways influenced by the epigenome, transcriptome, proteome, and metabolome. ...

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
37 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients with endometriosis and non-endometriosis who are scheduled to undergo in vitro fertilization/ intracytoplasmic sperm injection treatment at our hospital; * Womens' age \<38 year; * Patients diagnosed with endometriosis through surgery, ultrasound or magnetic resonance imaging. Exclusion Criteria: * The patient suffers from a severe uterine leiomyoma or other serious diseases; * The patient previously underwent unilateral/bilateral oophorectomy due to the disease; * The patient was previously diagnosed with a tumor-related disease; * The patients with immune disorders or metabolic diseases; * The patient undergoes egg cell donation; * The patient underwent pre-implantation genetic diagnosis.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Second Hospital of Shandong University Jinan Shandong

More The Second Hospital of Shandong University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07558629 on ClinicalTrials.gov ↗ ← All trials in China